Signal transduction pathways are crucial for the immune system's response to vaccines, as they regulate how immune cells detect and respond to foreign pathogens. When a vaccine is administered, it interacts with immune cells such as dendritic cells or macrophages, triggering these signaling pathways. These pathways, such as the NF-kB pathway or those involving Toll-like receptors (TLRs), help initiate the immune response by activating transcription factors that stimulate the production of cytokines and other immune signaling molecules. By understanding these pathways, vaccine developers can design vaccines that better regulate the immune response, ensuring a more robust defense. Optimizing these pathways can improve vaccine efficacy by increasing the strength of the immune response, enhancing the production of antibodies, and ensuring long-term immunity. Additionally, it allows researchers to develop vaccines that balance immune activation, minimizing adverse effects while maximizing protective immunity against pathogens.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States